March 06, 2026

#147 -The REMIX Trial: Remibrutinib for Chronic Hives

40 minutes

If you have chronic hives and antihistamines aren't helping, there's a new treatment option to know about. In this episode of The Itch Review, we spotlight "Remibrutinib in Chronic Spontaneous Urticaria" published in The New England Journal of Medicine, March 2025.

This article looks at the REMIX trials, which tested whether remibrutinib, a BTK inhibitor, can help adults whose chronic spontaneous urticaria (CSU) is not controlled by antihistamines alone. Remibrutinib works differently from antihistamines. Instead of blocking histamine after it's released, it stops mast cells from releasing those itch-causing chemicals in the first place.

The FDA approved remibrutinib in September 2025.

What we cover in our episode about the REMIX trial:

Understanding CSU: Chronic spontaneous urticaria causes itchy hives and swelling for more than 6 weeks with no clear trigger, and antihistamines don't work for everyone.

How remibrutinib works: This BTK inhibitor stops mast cells from releasing chemicals like histamine, rather than blocking histamine after it's already released.

Why do two identical trials: Running the same study twice (REMIX-1 and REMIX-2) with different patients helps prove the results are real, not a fluke.

Key results: About half of patients reached well-controlled disease, and about 1 in 3 became completely clear of hives and itch.

Safety and side effects: Petechiae (tiny dots of bleeding under the skin) were the main thing to watch for, but most cases were mild and went away on their own.

DOWNLOAD THE INFOGRAPHIC

More resources about chronic hives

Chronic Spontaneous Urticaria - Allergy & Asthma Network

Chronic Urticaria Toolkit

What are hives?

All episodes on urticaria

***********

The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference.

***********

Made in partnership with The Allergy & Asthma Network.

Thanks to Novartis for sponsoring today’s episode.

This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

...more

View all episodes

By The Itch: Allergies, Asthma & Immunology

4.3

9292 ratings

March 06, 2026

#147 -The REMIX Trial: Remibrutinib for Chronic Hives

40 minutes

The FDA approved remibrutinib in September 2025.

What we cover in our episode about the REMIX trial:

Understanding CSU: Chronic spontaneous urticaria causes itchy hives and swelling for more than 6 weeks with no clear trigger, and antihistamines don't work for everyone.

How remibrutinib works: This BTK inhibitor stops mast cells from releasing chemicals like histamine, rather than blocking histamine after it's already released.

Why do two identical trials: Running the same study twice (REMIX-1 and REMIX-2) with different patients helps prove the results are real, not a fluke.

Key results: About half of patients reached well-controlled disease, and about 1 in 3 became completely clear of hives and itch.

Safety and side effects: Petechiae (tiny dots of bleeding under the skin) were the main thing to watch for, but most cases were mild and went away on their own.

DOWNLOAD THE INFOGRAPHIC

More resources about chronic hives

Chronic Spontaneous Urticaria - Allergy & Asthma Network

Chronic Urticaria Toolkit

What are hives?

All episodes on urticaria

***********

Made in partnership with The Allergy & Asthma Network.

Thanks to Novartis for sponsoring today’s episode.

This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

...more